A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors
Lin Lin,Hongming Pan,Xingya Li,Chengling Zhao,Jiangtao Sun,Xingsheng Hu,Yiping Zhang,Mengzhao Wang,Xiubao Ren,Xiaoyong Luo,Guoyong Shan,Ai-Min Hui,Zhuli Wu,Huilong Liu,Ling Tian,Yuankai Shi
DOI: https://doi.org/10.1016/j.lungcan.2022.01.025
IF: 6.081
2022-04-01
Lung Cancer
Abstract:IntroductionThere are no targeted therapies for EGFR-mutated non-small cell lung cancer (NSCLC) without EGFR T790M mutation after progression on EGFR tyrosine kinase inhibitors (TKIs). We evaluated the safety, tolerability, antitumor activity, and pharmacokinetics of FCN-411, an inhibitor of EGFR, HER2, and HER4, in EGFR TKI-treated, EGFR-mutated advanced NSCLC.MethodsThis was a phase I, open-label, multicenter, dose-escalation/dose-expansion study in China. Adult patients with stage IIIB/V NSCLC harboring EGFR mutations (exon 18/19/20/21) who had progressed on prior EGFR-TKIs were enrolled. In the dose-escalation phase, patients received 4–16 mg FCN-411 once daily until the maximum tolerated dose (MTD). In the dose-expansion phase, patients received FCN-411 at the recommended phase II dose (RP2D) continuously in 21-day cycles. The primary endpoints were safety, tolerability, MTD, and RP2D.ResultsAs of February 1, 2021, 77 patients were enrolled, including 30 with detectable EGFR T790M mutation in tumors. No dose-limiting toxicities were observed. The RP2D was defined as 8 mg based on safety, pharmacokinetics, and antitumor activity. The most common grade ≥3 treatment-emergent adverse events among all patients were diarrhea (8; 10.4%) and dermatitis acneiform (7; 9.1%). Ten of 67 evaluable patients achieved confirmed partial response, with an objective response rate (ORR) of 14.9% (95% confidence interval [CI], 8.3–24.0); at 8 mg, ORR was 14.0% (7.2–23.9). Moreover, 39 patients achieved stable disease across all doses (disease control rate, 73.1%; 95% CI, 60.9–83.2). Median progression-free survival was 4.1 months (95% CI, 2.9–5.3). Median duration of response and overall survival were not reached. ORR was 20.5% and 7.4% in patients without and with EGFR T790M, respectively.ConclusionsFCN-411 was well tolerated up to 16 mg once daily and demonstrated antitumor activity in patients with EGFR-mutated NSCLC after progression on EGFR TKIs, especially in those without EGFR T790M mutation.
oncology,respiratory system